{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:11:28Z","timestamp":1761919888982,"version":"build-2065373602"},"reference-count":47,"publisher":"Elsevier BV","issue":"10-12","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Genetics"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.cancergen.2014.10.003","type":"journal-article","created":{"date-parts":[[2014,10,15]],"date-time":"2014-10-15T16:49:35Z","timestamp":1413391775000},"page":"503-510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Transient presence of clonal chromosomal aberrations in Ph-negative cells in patients with chronic myeloid leukemia remaining in deep molecular response on tyrosine kinase inhibitor treatment"],"prefix":"10.1016","volume":"207","author":[{"given":"Micha\u0142","family":"Gniot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u0142a\u017cej","family":"Ratajczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Lewandowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Lehmann-Kopyd\u0142owska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Jarmu\u017c-Szymczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mieczys\u0142aw","family":"Komarnicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergen.2014.10.003_bib1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.cancergen.2014.10.003_bib2","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.cancergen.2014.10.003_bib3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergen.2014.10.003_bib4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1634\/theoncologist.6-3-233","article-title":"STI571: targeting BCR-ABL as therapy for CML","volume":"6","author":"Mauro","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.cancergen.2014.10.003_bib5","first-page":"1126","article-title":"International randomized study of interferon vs. STI571 (IRIS) 8-Year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.cancergen.2014.10.003_bib6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cancergen.2014.10.003_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2165\/00126839-200607020-00007","article-title":"Dasatinib: BMS 354825","volume":"7","year":"2006","journal-title":"Drugs R D"},{"key":"10.1016\/j.cancergen.2014.10.003_bib8","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2014.10.003_bib9","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergen.2014.10.003_bib10","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cancergen.2014.10.003_bib11","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/blood-2007-08-109330","article-title":"Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells","volume":"111","author":"Wu","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2014.10.003_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cancergencyto.2010.02.003","article-title":"Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications","volume":"199","author":"Zaccaria","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergen.2014.10.003_bib13","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"unstructured":"National Comprehensive Cancer Network. Chronic Myelogenous Leukemia (version 3.2014). Available from: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf. Accessed June 23, 2014.","key":"10.1016\/j.cancergen.2014.10.003_bib14"},{"key":"10.1016\/j.cancergen.2014.10.003_bib15","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2018real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)\u2013a Europe against cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergen.2014.10.003_bib16","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2013a Europe against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergen.2014.10.003_bib17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2014.10.003_bib18","first-page":"454","article-title":"[Standardization of quantitative detection of BCR-ABL gene expression by RQ-PCR in patients with chronic myeloid leukemia in cooperation with European Leukemia Net]","volume":"67","author":"Sacha","year":"2010","journal-title":"Przegl Lek"},{"year":"2009","author":"International Standing Committee on Human Cytogenetic Nomenclature","series-title":"ISCN 2009: an international system for human cytogenetic nomenclature","key":"10.1016\/j.cancergen.2014.10.003_bib19"},{"key":"10.1016\/j.cancergen.2014.10.003_bib20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12032-012-0443-1","article-title":"Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia","volume":"30","author":"Bozkurt","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.cancergen.2014.10.003_bib21","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/cncr.11729","article-title":"Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase","volume":"98","author":"Medina","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.cancergen.2014.10.003_bib22","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/blood-2002-07-2053","article-title":"Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority","volume":"101","author":"Bumm","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2014.10.003_bib23","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.leu.2402848","article-title":"Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate","volume":"17","author":"O'Dwyer","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergen.2014.10.003_bib24","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2003-06-1943","article-title":"Chromosomal abnormalities in Ph\u2212 cells of patients on imatinib","volume":"102","author":"McMullin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2014.10.003_bib25","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/sj.leu.2403399","article-title":"Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia","volume":"18","author":"Terre","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergen.2014.10.003_bib26","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1080\/10428190410001723278","article-title":"Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib","volume":"45","author":"Loriaux","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cancergen.2014.10.003_bib27","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/cncr.22936","article-title":"The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells","volume":"110","author":"Deininger","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.cancergen.2014.10.003_bib28","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2007-01-070045","article-title":"Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"110","author":"Jabbour","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2014.10.003_bib29","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.leukres.2009.08.032","article-title":"Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib","volume":"34","author":"Paquette","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.cancergen.2014.10.003_bib30","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nature07943","article-title":"The cancer genome","volume":"458","author":"Stratton","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.cancergen.2014.10.003_bib31","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0165-4608(03)00198-5","article-title":"Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases","volume":"147","author":"Herens","year":"2003","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergen.2014.10.003_bib32","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1002\/cncr.22699","article-title":"Characterization of Ph-negative abnormal clones emerging during imatinib therapy","volume":"109","author":"Abruzzese","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.cancergen.2014.10.003_bib33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2014.10.003_bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cancergencyto.2010.08.017","article-title":"Factors influencing a second myeloid malignancy in patients with Philadelphia-negative -7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia","volume":"204","author":"Groves","year":"2011","journal-title":"Cancer Genet"},{"key":"10.1016\/j.cancergen.2014.10.003_bib35","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1751-553X.2007.00991.x","article-title":"Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia","volume":"30","author":"Kim","year":"2008","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.cancergen.2014.10.003_bib36","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1097\/00029330-200711020-00012","article-title":"Molecular genetic evidence of Y chromosome loss in male patients with hematological disorders","volume":"120","author":"Zhang","year":"2007","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.cancergen.2014.10.003_bib37","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/ng.2966","article-title":"Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer","volume":"46","author":"Forsberg","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.cancergen.2014.10.003_bib38","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2009.019109","article-title":"Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy","volume":"95","author":"Lippert","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.cancergen.2014.10.003_bib39","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2174\/138920212802510466","article-title":"On the power of additional and complex chromosomal aberrations in CML","volume":"13","author":"Greulich-Bode","year":"2012","journal-title":"Current Genomics"},{"key":"10.1016\/j.cancergen.2014.10.003_bib40","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2141.2004.05215.x","article-title":"Clonal karyotypic abnormalities in Philadelphia negative cells of CML patients treated with imatinib: is it under-reported and does it have any clinical significance?","volume":"127","author":"O'Shea","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cancergen.2014.10.003_bib41","doi-asserted-by":"crossref","first-page":"14483","DOI":"10.1073\/pnas.0605245103","article-title":"Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor","volume":"103","author":"Sloand","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cancergen.2014.10.003_bib42","doi-asserted-by":"crossref","first-page":"21382","DOI":"10.1074\/jbc.M709953200","article-title":"Role of c-Abl kinase in DNA mismatch repair-dependent G2 cell cycle checkpoint arrest responses","volume":"283","author":"Wagner","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cancergen.2014.10.003_bib43","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/sj.leu.2403861","article-title":"Induction of centrosome and chromosome aberrations by imatinib in\u00a0vitro","volume":"19","author":"Fabarius","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergen.2014.10.003_bib44","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3324\/haematol.11064","article-title":"Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure","volume":"92","author":"Fabarius","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.cancergen.2014.10.003_bib45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4238\/2012.February.10.2","article-title":"Philadelphia-negative chromosomal evolution during treatment for chronic myeloid leukemia","volume":"11","author":"Hsiao","year":"2012","journal-title":"Genet Mol Res"},{"key":"10.1016\/j.cancergen.2014.10.003_bib46","first-page":"3767","article-title":"Treatment results and malignant complications in patients on long-term treatment with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML)","volume":"120","author":"Kyo","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.cancergen.2014.10.003_bib47","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"}],"container-title":["Cancer Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776214002294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776214002294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:39:37Z","timestamp":1761896377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210776214002294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":47,"journal-issue":{"issue":"10-12","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S2210776214002294"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergen.2014.10.003","relation":{},"ISSN":["2210-7762"],"issn-type":[{"type":"print","value":"2210-7762"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transient presence of clonal chromosomal aberrations in Ph-negative cells in patients with chronic myeloid leukemia remaining in deep molecular response on tyrosine kinase inhibitor treatment","name":"articletitle","label":"Article Title"},{"value":"Cancer Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cancergen.2014.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}